28 July, 2017
The firm has a 50 day moving average of GBX 1,644.51 and a 200 day moving average of GBX 1,627.71. Renaissance Technologies LLC boosted its stake in GlaxoSmithKline PLC by 42.7% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in GlaxoSmithKline PLC by 1,747.4% in the first quarter. Finally, M Holdings Securities Inc. boosted its position in shares of GlaxoSmithKline PLC by 13.3% in the fourth quarter. Zacks Investment Research downgraded shares of GlaxoSmithKline PLC from a "buy" rating to a "hold" rating in a research note on Friday, July 21st. The Company has 52-week high of $45.58 and 52-week low of $37.20. Four analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have assigned a buy rating to the stock. If you are viewing this article on another site, it was illegally copied and reposted in violation of global trademark and copyright law. The stock has a market cap of $99.19 billion, a PE ratio of 45.41 and a beta of 1.04. FMR LLC now owns 23,635,038 shares of the pharmaceutical company's stock valued at $996,452,000 after buying an additional 2,482,009 shares during the last quarter. GlaxoSmithKline plc now has a consensus rating of Hold and a consensus target price of GBX 1,731.04 ($22.55).
On 4/28/2016 GlaxoSmithKline PLC announced a dividend of $0.55 with an ex dividend date of 5/11/2016 which will be payable on 7/14/2016. The pharmaceutical company reported $0.62 earnings per share for the quarter, hitting the consensus estimate of $0.62.
GlaxoSmithKline plc (GSK) performance during the last one year Degraded -7.5 percent, while its year to date (YTD) performance showed a Positive trend of 6.08 percent. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company's stock valued at $102,000 after buying an additional 753 shares during the period.
10/17/2016 - GlaxoSmithKline PLC had its "buy" rating reiterated by analysts at Bryan Garnier.
On 7/26/2017 GlaxoSmithKline PLC announced a Quarterly dividend of $0.49 with an ex dividend date of 8/9/2017 which will be payable on 10/12/2017. The company had revenue of $9.36 billion during the quarter, compared to analysts' expectations of $9.52 billion. J P Morgan Chase & Co reissued a neutral rating and issued a GBX 1,750 ($22.80) price target on shares of GlaxoSmithKline plc in a research note on Saturday, May 20th. Institutional investors and hedge funds own 8.98% of the company's stock. Dividends are mostly given in terms of cash payments, property or as shares of stock. Net profit margin of the company was recorded at 5.8 percent, operating profit margin was 12.4 percent, whereas gross profit margin stands at 68.4 percent. The company had a trading volume of 9,355,119 shares. Bronfman E.L. Rothschild L.P. increased its position in GlaxoSmithKline PLC by 45.4% in the first quarter. Heritage Trust Co acquired a new position in GlaxoSmithKline PLC during the first quarter valued at $123,000.
While looking at the Stock's Performance, GlaxoSmithKline plc now shows a Weekly Performance of -3.7%, where Monthly Performance is -7.31%, Quarterly performance is 0.42%, 6 Months performance is 5.07% and yearly performance percentage is -7.5%. Berenberg Bank raised shares of GlaxoSmithKline PLC from a hold rating to a buy rating in a report on Friday, May 26th. Guardian Investment Management now owns 21,100 shares of the pharmaceutical company's stock valued at $910,000 after buying an additional 500 shares during the period. UBS AG set a GBX 1,600 ($20.84) price objective on GlaxoSmithKline plc and gave the company a neutral rating in a report on Wednesday.
GlaxoSmithKline plc has its outstanding Shares of 2.44 Billion. GlaxoSmithKline PLC has a dividend payout ratio of 68.1% meaning its dividend is sufficiently covered by earnings. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The corporation focuses on its analysis across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.